TenX Keane Acquisition (TENK) is a Blank Checks company listed on NASDAQ. There were no new wire items for TENK in the last 30 days. The most recent was published Aug 15, 2024.
Latest news
25 items- 13D/GAmendment: SEC Form SC 13D/A filed by TenX Keane AcquisitionSC 13D/A - CITIUS ONCOLOGY, INC. (0001851484) (Subject)
- INSIDERSEC Form 4 filed by Director Dutia Suren G4 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)
- INSIDERSEC Form 4 filed by Director Holubiak Myron Z4 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)
- INSIDERSEC Form 4 filed by Chief Medical Officer Czuczman Myron4 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Mazur Leonard L4 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Bartushak Jaime4 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)
- INSIDERSEC Form 4 filed by Director Mcgrath Dennis M4 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)
- INSIDERSEC Form 4 filed by Large owner Citius Pharmaceuticals, Inc.4 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)
- INSIDERSEC Form 4 filed by Director Webb Carol4 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)
- INSIDERSEC Form 3 filed by new insider Dutia Suren G3 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)
- INSIDERSEC Form 3 filed by new insider Smith Robert Joseph3 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)
- INSIDERSEC Form 3 filed by new insider Holubiak Myron Z3 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)
- INSIDERSEC Form 3 filed by new insider Czuczman Myron3 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)
- INSIDERSEC Form 3 filed by new insider Mazur Leonard L3 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)
- INSIDERSEC Form 3 filed by new insider Bartushak Jaime3 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)
- INSIDERSEC Form 3 filed by new insider Mcgrath Dennis M3 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)
- INSIDERNew insider Citius Pharmaceuticals, Inc. claimed ownership of 65,627,262 shares (SEC Form 3)3 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)
- INSIDERSEC Form 3 filed by new insider Webb Carol3 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)
- SECSEC Form 25-NSE filed by TenX Keane Acquisition25-NSE - CITIUS ONCOLOGY, INC. (0001851484) (Subject)
- SECSEC Form 10-Q filed by TenX Keane Acquisition10-Q - CITIUS ONCOLOGY, INC. (0001851484) (Filer)
- PRTenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination, and Provides Market UpdateTenX Keane shareholders voted to approve the previously announced merger with Citius Oncology at an extraordinary general meeting held on August 2, 2024 Post-merger company expected to trade on Nasdaq as Citius Oncology, Inc. (CTOR) New York, NY, Aug. 09, 2024 (GLOBE NEWSWIRE) -- On August 7, 2024, TenX Keane Acquisition (NASDAQ:TENKU, TENK, TENKR))) ("TenX"), a publicly traded special purpose acquisition company, was notified by The Nasdaq Stock Market that trading in TenX's securities had been halted for "additional information requested" from the company. The trading halt was imposed following volatility in the trading price and volume of TenX's securities on Wednesday, August 7, 202
- PRTenX Keane Acquisition Shareholders Approve Previously Announced Merger to Form Citius Oncology, Inc., a Publicly Listed Subsidiary of Citius PharmaceuticalsTenX Keane shareholders voted to approve the previously announced merger with Citius Oncology at an extraordinary general meeting held on August 2, 2024 Post-merger company expected to trade on Nasdaq as Citius Oncology, Inc. Transaction expected to support commercialization of LYMPHIR, if approved, and exploration of additional oncology assets New York, NY, Aug. 05, 2024 (GLOBE NEWSWIRE) -- TenX Keane Acquisition (NASDAQ:TENKU, TENK, TENKR))) (the "TenX"), a publicly traded special purpose acquisition company, today announced that on August 2, 2024, at the extraordinary general meeting, its shareholders voted to approve the previously announced business combination with the wholly own
- PRCitius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Inc.Citius Pharmaceuticals to receive 65.6 million shares of TenX Keane, which will be renamed Citius Oncology, Inc. Citius Pharmaceuticals to retain approximately 90% majority control post transaction Post-merger company expected to trade on Nasdaq as Citius Oncology, Inc. Transaction expected to support commercialization of LYMPHIR, if approved, and exploration of additional oncology assets CRANFORD, N.J., Aug. 5, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ:CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that shareholders of TenX Keane
- SECTenX Keane Acquisition filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits8-K - TenX Keane Acquisition (0001851484) (Filer)
- SECSEC Form 425 filed by TenX Keane Acquisition425 - TenX Keane Acquisition (0001851484) (Subject)
TENK FAQ
6 questionsWhat is the latest news on TENK?
Quantisnow has not tracked any new filings, ratings or press releases for TENK in the last 30 days. The most recent wire item was published on August 15, 2024.Where does TENK stock trade?
TenX Keane Acquisition (TENK) is listed on NASDAQ.What sector and industry is TENK in?
TenX Keane Acquisition operates in the Finance sector, Blank Checks industry.When did TenX Keane Acquisition go public?
TenX Keane Acquisition (TENK) completed its IPO in 2022.What companies are similar to TENK?
Notable peers in the same industry include INV (Innventure Inc.), PRE (Prenetics Global Limited), OXSQ (Oxford Square Capital Corp.), TACO (Berto Acquisition Corp.), ILLU (Illumination Acquisition Corp I). Compare TENK side-by-side with any of them on Quantisnow.How can I track TENK on Quantisnow?
Quantisnow aggregates TenX Keane Acquisition's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TENK to receive live email and push alerts on every new disclosure.